Drug–drug cocrystals and coamorphous systems, both comprising two drugs in a single phase, can be applied to concurrently improve the physicochemical properties of the involved drugs. The comparative ...

Src, a non-receptor tyrosine kinase, is involved in various cellular processes including cell division, motility, adhesion, angiogenesis, and survival. RNAi therapy, particularly siRNA, aims to silenc...

Glioblastoma multiforme (GBM) is the most dangerous type of brain cancer because of spontaneous microvascular growth, which leads to damage to nearby brain tissues. GBM affects a huge population acros...

Un nuevo hidrogel termo-sensible con exosomas de ginseng para el tratamiento de la periodontitis Una investigación publicada en *Molecular Pharmaceutics* presenta un novedoso sistema de administración de fármacos para el tratamiento de la periodontitis. El estudio desarrolla un hidrogel termo-sensible cargado con exosomas derivados de ginseng. Este enfoque busca aprovechar las propiedades antiinflamatorias y regenerativas de los exosomas de plantas, encapsulándolas en un vehículo que puede inyectarse y gelificarse en el sitio de la infección periodontal.

A Sonic Key to the Inner Ear: Microbubbles for Targeted Drug Delivery A recent advance in Molecular Pharmaceutics details a novel drug delivery system using acoustically mediated microbubbles to target the inner ear. This approach represents a significant step in overcoming the formidable biological barrier of the blood-labyrinth, which has long hindered effective pharmacotherapy for hearing and balance disorders. The technique leverages the physical properties of microbubbles, which can be collapsed using focused ultrasound to temporarily increase local permeability, thereby allowing therapeutic agents to reach their intended site of action with greater precision and potentially reduced systemic exposure.

A targeted nanoparticle strategy for halting renal fibrosis A new study in *Molecular Pharmaceutics* presents a novel therapeutic approach for renal fibrosis using chondroitin sulfate-based nanoparticles. These nanoparticles are engineered to be reactive to reactive oxygen species (ROS) and specifically target activated myofibroblasts by binding to CD44 receptors, which are overexpressed in fibrotic tissue. This targeted delivery system aims to concentrate therapeutic agents directly at the site of disease, potentially improving efficacy while minimizing systemic side effects.

A targeted nanoparticle therapy emerges for renal fibrosis A new study in *Molecular Pharmaceutics* details the development of a chondroitin sulfate-based nanoparticle designed to treat renal fibrosis. The nanoparticles are engineered to be reactive to reactive oxygen species (ROS) and specifically target activated myofibroblasts by binding to CD44 receptors, which are overexpressed in fibrotic tissue. This targeted approach aims to deliver therapeutic agents directly to the cells driving fibrosis, a common pathological endpoint in chronic kidney diseases, potentially offering a more precise and effective treatment strategy.

A New Frontier in Fibrosis: Targeting Myofibroblasts with Smart Nanoparticles A new study in *Molecular Pharmaceutics* presents a novel therapeutic strategy for renal fibrosis using chondroitin sulfate-based nanoparticles. These nanoparticles are engineered to be reactive to reactive oxygen species (ROS), a hallmark of fibrotic tissue, and are designed to specifically target activated myofibroblasts via CD44 receptors. This targeted, stimulus-responsive approach aims to deliver therapy directly to the cells driving pathological tissue scarring, potentially offering a more precise and effective treatment for fibrotic diseases.

A targeted nanoparticle strategy for halting renal fibrosis A new study in *Molecular Pharmaceutics* presents a novel immunotherapy approach for treating renal fibrosis. Researchers have developed nanoparticles made from chondroitin sulfate that are engineered to be reactive to reactive oxygen species (ROS). These nanoparticles are designed to specifically target activated myofibroblasts, the key drivers of tissue scarring, by binding to CD44 receptors that are overexpressed on these cells.

Welcome to the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical TechnologyIn continuation of the

This award recognizes three early-career authors, highlighting their exceptional research published in the journal and the profound impact it has had on the field of molecular pharmaceutics. Learn…